Biotinylated Human KIR2DL3 Protein
Catalog No: KIR2DL3-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
Product overview
Recombinant Biotinylated Human KIR2DL3 Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues His22-His245 (UniProt accession: P43628).
Product Details
- Molecular Aliases
- cl-6; KIR2DL3; KIRCL23; KIR-K7b; KIR-K7c; NKAT; NKAT2; NKAT-2; NKAT2A; CD158b; CD158B2; GL183; KIR2DS5; NKAT2B;cl6
- Protein Length
- His22-His245
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 27.3 kDa. Due to glycosylation, the protein migrates to 45-52 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human KIR2DL3 on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.
The purity of Biotinylated Human KIR2DL3 is greater than 95% as determined by SEC-HPLC.
Background
KIR2DL3 (2DL3, formerly NKAT2, designated CD158b2) is a 341 amino acid (aa) type I transmembrane glycoprotein that belongs to the human killer cell Ig‑like receptor (KIR) family of molecules. KIRs are expressed on human CD56dim NK cells and T cell subsets, and regulate effector functions in the innate immune system.KIR2DL3 is a receptor on natural killer (NK) cells for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7). Inhibits the activity of NK cells thus preventing cell lysis.
References
- Yoon S R, Kim T D, Choi I. Understanding of molecular mechanisms in natural killer cell therapy[J]. Experimental & Molecular Medicine, 2015, 47(2):e141.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.